Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of the study is to test the efficacy of 2 tablets (twice daily) of ABT-712, compared to placebo, administered over a 4-week period in participants with moderate to severe mechanical chronic low back pain (CLBP).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AbbVie (prior sponsor, Abbott)
• Treatments: Acetaminophen; Hydrocodone

Criteria

Inclusion Criteria:

• Adult male and female subjects who voluntarily sign the informed consent

• Diagnosis of CLBP of 6 months duration

Exclusion Criteria:

• Incapacitated or bedridden subjects

• Subjects with history of surgical or invasive intervention